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IDENTIFYING MULTISYSTEM INFLAMMATORY SYNDROME
IN CHILDREN AFTER COVID-19 INFECTION
Anthony McKeiver, OMS-IV1; Gautam J. Desai, DO, FACOFP dist.1; W. Joshua Cox, DO, FACOFP2
Kansas City University College of Osteopathic Medicine – Division of Primary Care, Kansas City, MO
Kansas City University, Kansas City, MO

1
2

KEYWORDS:
COVID-19
MIS-C
Severe acute
respiratory system

Introduction: Since its discovery, the novel coronavirus disease 2019 (COVID-19) has evolved into
a global pandemic that has affected millions. The pediatric population was once thought to be
mostly spared from the SARS-CoV-2 virus. However, a severe hyperinflammatory sequela of the
virus known as multisystem inflammatory syndrome in children (MIS-C) has since been identified
and poses a great risk to pediatric morbidity and mortality. The goal of this manuscript is to clarify
and characterize MIS-C as a diagnosis, including current management and future considerations.
Methods: A thorough literature search was performed using Google Scholar and PubMed
databases for articles published January 2020 through August 2021.
Results: A two-tiered diagnostic approach was created for any pediatric patient presenting with
fever and an epidemiologic link to SARS-CoV-2. The mean age at time of diagnosis was 9.3 years
old, with 56.8% of patients identifying as male and the majority identifying as either Hispanic
(36.5%) or Black (35.1%). Common signs and symptoms included fever, cough, tachycardia and
tachypnea. Current treatment recommendations included IVIG, glucocorticoids, and aspirin, with
the more severe cases needing hospitalization and immune modulator therapy. Discussion: MIS-C
is a serious and potentially fatal sequelae after COVID-19 infection in the pediatric population.
Much is still unknown regarding the long-term effects of MIS-C. Further emphasis should be
placed on identifying definitive treatment and preventative strategies. Osteopathic family
physicians are the primary providers for many of the patients who may present with signs and
symptoms of MIS-C, and familiarity with the workup and treatment can help improve care.

INTRODUCTION
On December 31, 2019, the World Health Organization (WHO)
was first notified by a group of scientists in China of a group of
unexplained cases occurring in Wuhan, China and presenting as
a pneumonia-like illness. Over the next 18 months, this unknown
illness would become known around the world as the novel
coronavirus disease 2019 (COVID-19), which has developed into
a global pandemic with almost 200 million confirmed cases and
over 4 million reported deaths as of the start of August 2021.1
During this time, much surrounding COVID-19, including its
diagnosis, management and prevention, has continued to evolve.
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The causative agent—severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)—continues to spread across the globe
despite continued efforts to contain the virus.2,3,4 The development of a vaccine has helped to decrease transmission rates,
hospital admissions and overall mortality.4 However, new COVID-19
variants, skepticism and misinformation surrounding the vaccine,
and social and political biases, have made controlling the spread
of SARS-CoV-2 difficult.5,6
While in adults the presentation and severity of COVID-19 can vary
greatly, it was initially thought that children were mostly spared
from showing signs and symptoms of the virus, and therefore
assumed to have lower rates of infectivity.7,8 In an early study of
171 children with confirmed COVID-19 diagnoses, it was found
that only 3 cases needed intensive care unit admission and only
1 case resulted in death.9 These results suggested that children
were less likely to be infected by SARS-CoV-2, and those who were
infected had a milder clinical course when compared to adults.
However, most of the children in these studies were symptomatic
when diagnosed, and therefore only followed until symptom
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resolution. Because many children infected with COVID-19 are
asymptomatic, this made determining an exact rate of infectivity
difficult for this patient population, as well as challenging when
trying to identify any possible negative effects the virus could have
in both symptomatic patients and asymptomatic carriers.
In April 2020, a United Kingdom report highlighted a group of 8
previously healthy children presenting with a hyperinflammatory state and signs of multiple-organ damage.10 While never
tested directly, all of these cases were linked to recent COVID-19
exposure. This newly identified hyperinflammatory syndrome
associated with COVID-19 was eventually named by the U.S.
Centers for Disease Control and Prevention (CDC) as multisystem
inflammatory syndrome in children (MIS-C) and has become a
serious complication of the virus with morbidity and mortality
rates in children much higher than previously suspected.11,12
With the discovery of new variants, rates of COVID-19 and
MIS-C diagnosis in children have only continued to increase. Since
there is currently no diagnostic testing for MIS-C, it presents a
major public health concern for the pediatric population. The
authors wish to clarify and further characterize the epidemiology,
pathogenesis, clinical identification, symptomatology, diagnostic
criteria, management and long-term outcomes of MIS-C,
including new advancements and understanding of this novel
syndrome since its discovery.

METHODS
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A thorough search of available literature in the English language
was performed using Google Scholar and PubMed databases for
articles published from January 2020 through August 2021. Due
to the rapidly changing and continued evolving understanding
of COVID-19 and MIS-C, multiple various search criteria were
used, including “coronavirus disease 2019;” “severe acute
respiratory syndrome coronavirus 2;” “multisystem inflammatory
syndrome in children;” “hyperinflammatory syndrome;” “Kawasaki
disease;” “toxic shock syndrome;” “shock;” “children;” “pediatrics;”
“pandemic;” and “vaccine.”

RESULTS
Several meta-analyses and systematic reviews13–18 have been
conducted since the discovery of MIS-C, encompassing over 500
published articles to date. A summary of findings is detailed
below, including diagnostic criteria, demographics, clinical characteristics, laboratory and imaging findings, treatment and management, and clinical outcomes and complications of patients with
MIS-C.

Diagnostic criteria
The CDC and WHO have similar case definitions for diagnosing
MIS-C, both of which are outlined in Table 1.19,20 While these criteria
were initially used to make a formal diagnosis, as MIS-C became
more widespread, a tiered diagnostic approach was adopted
for any patient presenting to the emergency department with
unremitting fever and an epidemiologic link to SARS-CoV-2.16,21

TABLE 1:
CDC and WHO case definitions of multisystem inflammatory
syndrome in children.
CRITERIA

CDC CASE DEFINITION

WHO CASE DEFINITION

Age

<21 years old

<19 years old

Fever

Fever >38.0°C (100.4°F) for ≥24 hours
or subjective fever lasting ≥24 hours

Fever for ≥3 days

Clinical
Presentation

2 or more organ system involvement:
o Cardiac
o Renal
o Respiratory
o Hematologic
o Gastrointestinal
o Dermatologic
o Neurological

2 or more of the following:
o Rash or non-purulent
conjunctivitis or muco-cutaneous inflammation
o Hypotension or shock
o Features of myocardial dysfunction, pericarditis, valvulitis, or
coronary abnormalities
o Evidence of coagulopathy
o Acute gastrointestinal problems

Inflammatory
Laboratory
Evidence

Including any of the following:
Elevated CRP, ESR, fibrinogen,
procalcitonin, D-dimer, ferritin, LDH,
IL-6, neutrophilia, lymphocytopenia
or hypoalbuminemia

1 or more of the following:
Elevated markers of inflammation such as ESR, CRP or procalcitonin

Diagnosis of
Exclusion

No alternative plausible diagnoses

No other obvious microbial cause of inflammation (including sepsis, or
bacterial shock syndromes)

Link to
SARS-CoV-2

Positive for current or recent SARSCoV-2 infection by RT-PCR, serology,
or antigen test or COVID-19 exposure
within the 4 weeks prior to onset of
symptoms

Evidence of COVID-19 (RT-PCR, antigen test, or serology positive)
or likely contact with patients with COVID-19
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This includes performing an initial evaluation screen (tier 1)
through measuring a complete blood count (CBC), complete
metabolic panel (CMP), erythrocyte sedimentation rate (ESR),
C-reactive protein (CRP) and SARS-CoV-2 PCR laboratory
values. If these results are consistent with MIS-C diagnosis, a
complete diagnostic evaluation (tier 2) should be performed. Tier 2
evaluation consists of more complex testing, including measuring
brain natriuretic peptide (BNP), troponin-T, procalcitonin,
ferritin, prothrombin time (PT), partial thromboplastin time (PTT),
D-dimer, fibrinogen, lactic dehydrogenase (LDH) and triglyceride
levels, as well as a cytokine panel, SARS-CoV-2 serology, blood
smear, electrocardiogram (ECG) and echocardiogram.21 Blood
cultures are also indicated for patients presenting with severe
symptoms, such as fever and 2 or more organ systems involvement.
The tier approach is a good evaluation design, as it permits
effective and cost-efficient screening for patients who may have
MIS-C. Since MIS-C is still a rare complication of SARS-CoV-2
infection with a current estimated incidence rate of 2 out of
200,000 individuals,22 it is not necessary to perform a full workup on each patient. However, in patients who exhibit signs and
symptoms of MIS-C, a second, more thorough evaluation should
be completed due to the severe cardiovascular and respiratory
complications that MIS-C can cause.

Demographics
The mean age of patients at time of diagnosis of MIS-C was 9.3
years old, with 56.8% of patients identifying as male.17 Patient
race/ethnicity varied, with 36.5% identifying as Hispanic, 35.1%

TABLE 2:

Black, 25.2% white, 16.2% Asian, and 14% other.18 Of all patients
diagnosed with MIS-C, 31% reported a previous comorbid
condition, the most common being a past medical history of
obesity or asthma.1

Clinical characteristics
All patient presentations met the criteria for MIS-C diagnosis. The
most common symptoms present at time of diagnosis were fever,
diarrhea, cough and abdominal pain. Common clinical signs were
mainly cardiovascular dysfunction (tachycardia, hypotension)
followed by respiratory dysfunction (tachypnea, low oxygen
saturation).14

Laboratory and imaging findings
The most common laboratory findings were elevated inflammatory
markers. Of these, the most elevated were ESR and CRP,
albeit these are considered non-specific markers of inflammation
for a variety of disease processes.17 While imaging was rarely
necessary at time of diagnosis, the most commonly performed was
echocardiography, and it frequently demonstrated decreased
cardiac ventricular function.
Because the clinical presentation and laboratory findings of
MIS-C can closely mimic other pediatric inflammatory diagnoses,
most especially Kawasaki disease, careful consideration must be
given in order to make the correct diagnosis. Kawasaki disease
is an acute inflammatory illness of unknown origin that was
originally founded in Japan in 1967 and primarily affects children
5 years of age and younger.12 Common initial signs and symptoms
include fever, a classic “strawberry” red tongue, rash, irritability and
fatigue,12 many of which are also seen in patients with MIS-C.

Comparison of MIS-C and Kawasaki Disease.
MIS-C

KAWASAKI DISEASE

Age

Older children and adolescents with
median ages of 8–11 years

Infant and younger children, 76% of affected children <5 years

Race and Ethnicity

Black and Hispanic descent

Asian descent

GI Symptoms

GI symptoms very common
(53%–92%)

GI symptoms less common (20%)

Myocardial Dysfunction
and Shock

Myocardial dysfunction common,
elevated BNP (73%), troponin (50%),
48% receive vasoactive support

Myocardial dysfunction much less common, normal troponin,
5% receive vasoactive support

Organ Dysfunction

Multiorgan dysfunction common

Multiorgan dysfunction uncommon

Inflammatory
Markers

Highly elevated CRP, ferritin,
procalcitonin and D-dimer,
lymphopenia and thrombocytopenia

Elevated CRP and D-dimer, normal ferritin, thrombocytosis

Treatment

IVIG, corticosteroids, IL-1 blocker,
IL-6 inhibitors

IVIG, corticosteroids, IL-1 blocker

Average
Outcomes

Fatality rate: 1.4%–1.7%

Fatality rate: 0.01%

Clinical Presentation:
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Table 2 below compares the most common presentations and
objective data for both MIS-C and Kawasaki disease.23,24 Utilizing
similar guidelines and algorithms as seen in Table 2 can greatly
impact patients’ medical decision making by allowing for accurate
diagnosis and subsequent management.

Symptomatic treatment, clinical management
and complications
The overall goal of MIS-C treatment is to stabilize the patient
and prevent life-threatening long-term complications, especially
any cardiac manifestations such as myocardial fibrosis/scarring
and coronary artery aneurysms. To prevent these complications,
most patients with confirmed MIS-C diagnosis were initially
stabilized with intravenous immune globulin (IVIG) as well as
adjunctive high-dose glucocorticoids for more severe cases.15–17
Daily therapeutic aspirin was also given to patients who had an
increased risk for coagulation and thrombosis, seen with elevated
D-dimer and fibrinogen.25

Recognizing MIS-C in pediatric patients after COVID-19
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Prevention
There is still much to elucidate surrounding the pathogenesis
and possible transmission of MIS-C. Because studies have shown
that MIS-C symptoms only present in relation to either active
COVID-19 infection or recent exposure, SARS-CoV-2 may act as a
trigger for immunomodulator in the development of MIS-C.28 There
is still confusion regarding why some children develop MIS-C, while
others do not. Some researchers suggest that pre-existing
conditions, race and severity of inflammatory response to
COVID-19 may play a role in its development.29 However, no
definitive cause or explanation has yet been proven. Therefore,
it is important to focus on preventative public health
policies that decrease transmission of SARS-CoV-2 to decrease
the incidence of MIS-C. These include strategies such
as wearing masks, socially distancing, proper hand hygiene and
encouraging COVID-19 vaccination.

Comparison to adults

According to several recent studies, IVIG and steroids are considered mainstay therapy for all patients diagnosed with MIS-C.15–17
IVIG therapy has been shown to reduce inflammatory markers in
MIS-C patients post-infusion, as well as result in overall decreased
rates of myocarditis compared to those who did not receive
IVIG.16,26 In a study that compared the use of combination IVIG and
steroid therapy versus IVIG monotherapy on the development
of cardiac dysfunction, it was found that there was a 44% risk
reduction in those patients receiving combination therapy.2

As knowledge surrounding MIS-C continues to evolve and
expand across the globe, there have been a few, rare, documented
cases of a similar hyperinflammatory response in connection with
recent COVID-19 exposure/diagnosis in adults.30 So called
“MIS-A” because they are occurring in adults at least 21 years of
age, these cases are being considered the same as MIS-C, with
similar treatment and management strategies. While MIS-C has
been recognized as a true syndrome in the pediatric population,
MIS-A is not as well defined.31

In more severe treatment-resistant cases of MIS-C, additional
treatment modalities should be initiated. For those patients
presenting with severe multisystemic shock, empiric broadspectrum antibiotic therapy should be started following a
blood culture draw.16,17,27 In the pediatric setting, an appropriate
antibiotic regimen of ceftriaxone plus vancomycin is usually
sufficient.27 If blood culture results are negative infection, antibiotic
therapy should be discontinued. Furthermore, in patients who
continued to worsen with decreased responses to IVIG, steroids
and/or aspirin alone, it is recommended that immune modulators
be initiated. These include anakinra (IL-1 receptor blocker),
tocilizumab (IL-6 inhibitor) and infliximab (anti-TNF-α), which can
be added to the treatment regimen and has been shown to have
improved outcomes in some patients.27 The efficacy of these
medications in the treatment of MIS-C, as well as other immune
modulators, are currently still being tested.

DISCUSSION

Finally, serial laboratory testing of systemic inflammatory
markers (ESR and CRP) and cardiac monitoring (troponin-T
and BNP) were performed to track the progress of the patient.
Additionally, other systemic complications, such as respiratory
distress, signs of hypercoagulability and development of systemic
shock were frequently monitored and evaluated.15–17

Since the first diagnosed cases in 2020, COVID-19 has rapidly
developed into a very serious global health concern. In part due to
its high infectivity rate, the SARS-CoV-2 virus has spread to nearly
every country in the world, resulting in hundreds of millions of
positive cases, and almost 4 million deaths worldwide. As a
relatively new pandemic, new discoveries about the virus and a
better understanding of its potential impact are continuing to
evolve. What was once thought of as a disease that mainly impacted
adult patients and the immunocompromised, it is now known that
COVID-19 also greatly impacts the pediatric population, with
hundreds of new cases occurring in the United States alone. Even
as variants spread, they are affecting many children, resulting in
increased pediatric morbidity and mortality rates.32
MIS-C, a very serious sequelae of SARS-CoV-2 infection, is
quickly becoming a public health concern. Due to the severity of
symptoms, as well as a current lack of understanding surrounding
future complications from the disease, much has been
discussed as to the best diagnostic, management and preventative
measures for children against MIS-C.
A two-tier diagnostic approach to MIS-C is the current
recommendation to minimize costs, time, and resources.16,21
Any pediatric patient who presents with fever, multi-organ
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symptoms, and recent association with COVID-19 should be
tested for SARS-CoV-2 infection and referred to a pediatric
infectious disease specialist/hospital unit. Symptomatic treatment
with IVIG, glucocorticoids, and/or aspirin, as well as close
monitoring for specific organ system findings is recommended
while serial inflammatory marker labs are performed
to aid in monitoring disease progression.17,26
Because MIS-C is a relatively new diagnosis, future emphasis
needs to be placed on monitoring the evolution of MIS-C
diagnosis, including more definitive testing and treatment
options. Additionally, future research should focus on determining
any sequalae for children who are diagnosed with MIS-C,
including possible organ system complications, weakened
immune systems, or risk for future infections. As current vaccines
are being authorized for children aged 12–18 years (as well as
possible authorization for younger ages in the future), it is
important to determine the efficacy of these vaccines in
preventing not only SARS-CoV-2 infection, but also
in preventing MIS-C diagnosis. As more is discovered surrounding the pathogenesis and clinical outcomes of MIS-C, it is important to consider new treatment and management strategies,
including immune modulators such as anakinra, tocilizumab,
infliximab and others, which are currently undergoing
clinical trials.33

CONCLUSION
Since its discovery in late 2019, COVID-19 infection from the SARSCoV-2 virus continues to pose a serious epidemiologic threat
to most of the world. The pediatric population faces a unique
and unexpected sequela of being infected by the virus after the
discovery of MIS-C hyperinflammatory syndrome, which has
affected more than 6000 pediatric individuals in the United States
alone. Due to the severity of symptoms, as well as a current lack
of understanding surrounding future complications from the
disease, much has been discussed as to the best diagnostic,
management, and preventative measures for children against
MIS-C. Following a two-tiered approach to diagnosis MIS-C is
critical for accurate identification of the syndrome. Current
evidence suggests symptomatic patients should be treated with
IVIG and glucocorticoids, as well as monitoring for worsening
organ dysfunction. As new discoveries and understandings of
MIS-C continue to evolve, it is important to continue following the
latest CDC and WHO guidelines for appropriate treatment and
management. The osteopathic family physician plays a key role in
primary care in the United States, and prompt identification and
treatment of this disorder is critical.
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